Revenue Update on Mediwound Ltd(NASDAQ:MDWD)

Mediwound Ltd(NASDAQ:MDWD) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $356.00K. Analysts estimated a revenue of $450.00K. Earnings per share were $-0.34. Analysts had estimated an EPS of $-0.23.

Mediwound Ltd (MDWD) made into the market gainers list on Thursdays trading session with the shares advancing 0.82% or 0.06 points. Due to strong positive momentum, the stock ended at $7.35, which is also near the day’s high of $7.38. The stock began the session at $7.38 and the volume stood at 17,107 shares. The 52-week high of the shares is $10.47 and the 52 week low is $5.66. The company has a current market capitalization of $161 M and it has 2,18,50,300 shares in outstanding.

MediWound Ltd. is a fully integrated biopharmaceutical company. The Company is focused on developing manufacturing and commercializing products to address unmet needs in the fields of severe burns chronic and other hard-to-heal wounds and connective tissue disorders. The Company’s biopharmaceutical product NexoBrid which is based on its patented proteolytic enzyme technology represents a new paradigm in burn care management and its clinical trials have demonstrated with statistical significance its ability to non-surgically and rapidly remove the eschar earlier upon patient admission without harming viable tissues. The Company launched NexoBrid in December 2013 in the European Union through its wholly-owned German subsidiary targeting a focused audience of burn specialists treating patients in burn centers and hospital burn units.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Mediwound Ltd - Is it time to Sell?

Top Brokerage Firms are advising their investors on Mediwound Ltd. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.